The growing number of private biopharma and diagnostic/therapeutic technology company financings completed in recent months masks an overall year-over-year decrease in the total value of those deals.
On Thursday, August 22nd from 4-6:00 pm there will be an open house for the fall courses in the “Advanced Studies in Technology Transfer” program at the Foundation for Advanced Education in the Sciences (FAES) Graduate School at NIH in the FAES Academic Center in NIH Building 10 in Bethesda, MD. For the semester beginning on Monday, September 9th there will be 9 courses available for the program given in either Rockville or Bethesda:
- TECH 495 – The FDA, Science, Health Policy and Regulation in an Uncertain Environment
- TECH 513A – Introduction to Technology Transfer – Issues & Processes
- TECH 521 – Tools for Technology Transfer Managers–Handling Intellectual Property, Collaborations, and Agreements
- TECH 565 – Biomedical Business Development for Scientists
- TECH 567 — International Strategic Partnering and Business Development
- TECH 575 – Accounting and IP Valuation for Non-Accountants
- TECH 583 — Patent Research for Non-Legal Practitioners
- TECH 588 – FDA Regulatory Strategy in Medical Product Development
- TECH 607 – Capstone Course in Technology Transfer
- PHAR 328 – FDA Perspective on Drug Development
More details can be found in the new 2019-20 course catalog (www.faes.org) with online registration for classes available. The Advanced Studies in Technology Transfer is an open enrollment program with class credits transferable into various graduate degree programs at the University of Maryland University College (UMUC) Graduate School and the University of Maryland Baltimore County (UMBC).
Technology Transfer Scholarships
FAES offers a limited number of partial tuition-remission scholarships for self-funding students. For deadlines and details on how to apply visit https://faes.org/tuition-and-funding .
Also as Department Chair, I’m happy to assist with any questions you might have about the program or individual courses.
Back when YC was getting started about 10 years ago, Paul Graham wrote some essays that predicted the way startup fundraising would change in the next decade – accurately, it turns out. Paul Graham predicted that there would be way more startups, that they’d be cheaper to start, that new kinds of investors would fund them, that founders would be more technical, and that founders would keep control of their companies. All of those seem to have come true.
Facility Logix Welcomes Two New Associate Project Managers to Bolster Project Teams – Facility Logix
Facility Logix, a leading life science consulting firm, has hired two new Associate Project Managers: Jocaro L. Dodd and Wayne Mitchell. The new Associate Project Managers will be instrumental in addressing the facility-related needs of the firm’s Owner’s Representation and Project Management clients.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Canton-based VitusVet, which built a health IT platform for vets, received investment from Nationwide Insurance as the company’s team continues to grow.
Joshna Seelam is closing in on her target.
The VCU graduate student is one of three members of Kilo Medical Solutions, a Richmond medical device startup that’s getting ever closer to launch.
County Executive Marc Elrich and Council Vice President Sidney Katz are embarking on a multi-pronged joint initiative: 4Business – Benchmarking to Be the Best for Business.
The objective is to engage the local business community in a grassroots campaign to assist businesses to locate, grow and prosper in Montgomery County.
Was your credit card unexpectedly rejected? Or have you spotted unfamiliar charges on your bank statement? These are just a couple signs of potential identity theft. (Source: Federal Trade Commission)
Once you realize your identity has been compromised, you need to act fast. But don’t panic; this guide will walk you through each step you need to take to be sure you recover as quickly as possible.
The gene therapy company has made three distinct moves over the past week that reinforce its intention to get products to market after a decade in business.